donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > BLUE bluebird bio > Detailed Quotes

BLUE bluebird bio

6.720
+0.410+6.49%
Trading Session 08/12 15:02 ET
High
7.000
Open
6.390
Turnover
42.91M
Low
6.330
Pre Close
6.310
Volume
6.37M
Market Cap
518.22M
P/E(TTM)
Loss
52wk High
17.850
Shares
77.12M
P/E(Static)
Loss
52wk Low
2.865
Float Cap
487.53M
Bid/Ask %
-12.50%
Historical High
152.883
Shs Float
72.55M
Volume Ratio
0.68
Historical Low
2.865
Dividend TTM
--
Div Yield TTM
450
P/B
2.88
Dividend LFY
--
Div Yield LFY
6696.93%
Turnover Ratio
8.77%
Amplitude
10.62%
Avg Price
6.740
Lot Size
1
Float Cap
487.53M
Bid/Ask %
-12.50%
Historical High
152.883
Shs Float
72.55M
Volume Ratio
0.68
Historical Low
2.865
Dividend TTM
--
P/B
2.88
Dividend LFY
--
Turnover Ratio
8.77%
Amplitude
10.62%
Avg Price
6.740
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...